Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with B-Precursor Adult Lymphoblastic Leukemia (ALL): Results of the Ongoing GMALL Bold Trial

Older patients (pts) with newly diagnosed ALL are ineligible for unmodified pediatric-based therapies. Even with age-adapted, dose-reduced regimens early death rates (ED) are considerable and overall survival (OS) poor. Thus, 412 pts treated according to the GMALL Elderly Protocol showed a CR rate of 75%, with 16% early death (ED) and the 3 years (yrs) OS was only 30%. Therefore, the GMALL study group developed a trial to evaluate Blinatumomab (Blina), a CD19 directed bi-specific T-cell engager, in sequence with chemotherapy in this patient population with high medical need (NCT 03480438). Blina replaces several cycles of chemotherapy being part of the standard GMALL protocol for older pts.